Fintel reports that on April 29, 2025, BTIG downgraded their outlook for InMode (NasdaqGS:INMD) from Buy to Neutral. Analyst ...

The high yield corporate bond market is not properly reflecting the rising probability of a U.S recession and is therefore proving a trade opportunity, says Jonathan Krinsky, technical strategist at ...

Block's shares fell 22% on Friday and were on track for the biggest intraday decline in five years after a 2025 profit ...

BTIG says the firm’s recent franchise checks show a “sharp inflection” in McDonald’s (MCD) April sales trends and a more optimistic tone from ...

NEW YORK, April 29, 2025--(BUSINESS WIRE)--BTIG announced today leadership changes within its healthcare investment banking division, appointing a new head of healthcare investment banking along ...

BTIG notes that shares of Tempus AI (TEM) are up on news that the company signed a $200M expanded strategic agreement with AstraZeneca (AZN) ...

BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut.

As of December 23, 2024, the average one-year price target for Hut 8 is $21.31/share. The forecasts range from a low of $7.82 to a high of $29.98. The average price target represents an increase ...

On Tuesday, BTIG analyst Sam Elber downgraded InMode Ltd . (NASDAQ:INMD) from Buy to Neutral, citing a continued contraction in the medical aesthetics market. The company, currently trading at $14 ...

In a report released today, Peter Saleh from BTIG maintained a Buy rating on Starbucks (SBUX – Research Report), with a price target of $105.00. Protect Your Portfolio Against M ...

On Tuesday, BTIG analyst Sam Elber downgraded InMode Ltd . (NASDAQ:INMD) from Buy to Neutral, citing a continued contraction in the medical aesthetics market. The company, currently trading at $14.26 ...